Compare H & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | H | PODD |
|---|---|---|
| Founded | 1957 | 2000 |
| Country | United States | United States |
| Employees | 50000 | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 17.0B |
| IPO Year | 2009 | 2007 |
| Metric | H | PODD |
|---|---|---|
| Price | $164.20 | $200.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | $179.00 | ★ $349.80 |
| AVG Volume (30 Days) | 608.8K | ★ 807.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | ★ $4,685,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | $110.54 | $24.59 |
| Revenue Next Year | $6.89 | $19.18 |
| P/E Ratio | ★ N/A | $56.86 |
| Revenue Growth | 5.78 | ★ 30.73 |
| 52 Week Low | $102.93 | $194.61 |
| 52 Week High | $180.53 | $354.88 |
| Indicator | H | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 31.16 |
| Support Level | $135.14 | N/A |
| Resistance Level | $170.87 | $299.75 |
| Average True Range (ATR) | 5.74 | 6.69 |
| MACD | 2.69 | -0.01 |
| Stochastic Oscillator | 95.30 | 20.92 |
Hyatt is an operator of owned (2% of total rooms) and managed and franchised (98%) properties across about 35 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 45% for the US, 31% rest of world, and 24% Asia-Pacific.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.